Nootropic Supplement Powder NSI-189/nootropic@ycgmp.com

본문 바로가기


Home > Product > Nootropic Supplement Powder NSI-189/nootropic@ycgmp.com
Selling leads
Nootropic Supplement Powder NSI-189/nootropic@ycgmp.com
Posting date : May 19, 2017
Membership
Free Member Scince May 19, 2017
FOB Price
$1
Min. Order Quantity
5g
Supply Abillity
500kg/mongth
Port
HK/Shanghai
Payment Terms
T/T Bank wire transfer,Western Union,MoneyGram,Bitcoin
Package
discreet package for delivery guarantee
Keyword :
Category
Contact
Cindy Lee
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Biopharmchem
Model Number
CAS: 1270138-40-3
HS-CODE
-
Package & Delivery Lead Time
Package
discreet package for delivery guarantee
Delivery Lead Time
5-7 working days
Detailed Description
Nootropic Supplement Powder NSI-189/nootropic@ycgmp.com
 
Product Name: NSI-189
CAS: 1270138-40-3
MF: C22H30N4O
MW: 366.4998
Purity: 99%
MP: 83°C-86°C
Grade: Pharmaceutical Grade
Appearance: White Powder
 
Description NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine.
 
Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression.
 
It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer's disease and age-related cognitive problems.
 
Development of NSI-189
 
NSI-189 is an experimental drug currently being developed and studied by Neuralstem Inc.. The researchers at Neuralstem recognized that a drug targeting the hippocampus could possibly alleviate the effects of sleep deprivation and exhaustion, and set out to find a drug that could induce neurogenesis. This preliminary research would eventually result in the drug NSI-189.
 
Clinical research on NSI-189 has been in the works since 2011, and a phase 1b trial was completed in July of 2014. Clinical phase 1 trials typically focus on finding the correct dosage range of the drug, which has been placed around 40 to 80 mg per day in the treatment of Major Depressive Disorder (MDD) and cognitive decline.
 
The phase 1b trial of NSI-189 was "a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD." Now that the trial has been completed, the results have been released, and they appear quite promising.
 
The study, which was conducted on 24 patients over the course of 28 days, found that NSI-189 administration reduced the symptoms of depression and cognitive decline significantly more than placebo. The drug was tolerated well by the subjects, and it "may also exhibit pro-cognitive properties associated with increases in prefrontal alpha coherence."
 
Mechanism of Action
 
Researchers have discovered that the disease-major depressive disorder (MDD)-leads to decreased hippocampal volume. Note that a healthy hippocampus is an excellent source of neural stem cells which lead to the production of neurons. Neurons on the other hand are critical for creating essential new connections in the brain. Through the production of new neurons in the hippocampal area, depression can be treated.
 
NSI-189 was developed to address three important aspects of depression including hippocampal volume, neurogenesis and neurotransmission. NSI-189 increases the volume within the hippocampus. In so doing, hippocampal volume and healthy brain cell density is increased thereby improving mod and cognitive performance.  Aside from increasing hippocampal volume, the drug also improves neuronal cell functionality. It works it promoting healthy neuronal cell growth whilst repair damaged areas in the brain.
 
Benefits
 
As mentioned above, the potential benefits of NSI-189 are:
Improvement in behavioral responses associated with depression.
Reversal of hippocampal atrophy.
May enhance memory and cognition through increase neurogenesis, particularly in depressed subjects.
Positive effects may persist after treatment ceases.
 
Dosage
 
Studies conducted to evaluate effects of NSI-189 revealed that 40 to 80 mg daily is effective in treating depression and cognitive symptoms amongst healthy patients. In these trials, there are no serious adverse events recorded. Generally, NSI-189 is well tolerated and safe for human use.

ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2024 ECROBOT.COM. All rights reserved.
Top